Summit gains on BMS drug discovery deal

Summit Corp. plc (LSE:SUMM) jumped 0.75p (30%) to 3.25p on Tuesday after granting Bristol-Myers Squibb Co. (NYSE:BMY) a license to use its Seglin technology to identify and develop drug candidates for...